Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARNA Arena Pharmaceuticals	$99.99	$97.65	$45.50 ▼ $100.00	$6.17B	0.55	1.56 million shs	107 shs
BBIO BridgeBio Pharma	$43.71 +2.0%	$37.93	$21.72 ▼ $45.48	$8.35B	1.15	2.50 million shs	2.46 million shs
BHVN Biohaven	$14.63 -0.9%	$16.74	$13.87 ▼ $55.70	$1.49B	0.91	1.29 million shs	753,892 shs
EBS Emergent Biosolutions	$6.99 -1.7%	$6.21	$4.02 ▼ $15.10	$379.40M	2.09	1.73 million shs	917,382 shs
FOLD Amicus Therapeutics	$6.16 +3.4%	$6.17	$5.51 ▼ $12.65	$1.88B	0.51	3.16 million shs	3.12 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARNA Arena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BBIO BridgeBio Pharma	0.00%	-2.57%	+14.95%	+39.32%	+74.82%
BHVN Biohaven	0.00%	+3.74%	-9.75%	-21.10%	-56.70%
EBS Emergent Biosolutions	0.00%	+10.17%	+10.08%	+54.30%	-7.29%
FOLD Amicus Therapeutics	0.00%	+3.79%	+0.90%	-17.93%	-37.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	4.7053 of 5 stars	4.5	2.0	0.0	3.9	2.4	3.3	0.6
BHVN Biohaven	3.4191 of 5 stars	4.5	1.0	0.0	0.0	2.7	2.5	0.6
EBS Emergent Biosolutions	4.327 of 5 stars	3.5	1.0	0.0	4.6	2.1	2.5	1.3
FOLD Amicus Therapeutics	3.7051 of 5 stars	3.4	1.0	0.0	4.3	0.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARNA Arena Pharmaceuticals	0.00	N/A	N/A	N/A
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	34.64% Upside
BHVN Biohaven	3.07	Buy	$58.46	299.60% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	105.05% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	163.56% Upside

Current Analyst Ratings Breakdown

Latest BHVN, FOLD, BBIO, EBS, and ARNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
5/19/2025	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
5/2/2025	FOLD Amicus Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $9.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARNA Arena Pharmaceuticals	$50K	123,305.67	N/A	N/A	$10.94 per share	9.14
BBIO BridgeBio Pharma	$221.90M	37.40	N/A	N/A	($7.71) per share	-5.67
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
EBS Emergent Biosolutions	$1.04B	0.36	$1.92 per share	3.64	$8.91 per share	0.78
FOLD Amicus Therapeutics	$528.29M	3.59	N/A	N/A	$0.65 per share	9.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARNA Arena Pharmaceuticals	-$616.43M	-$10.13	N/A	N/A	N/A	N/A	-69.83%	-62.35%	N/A
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.38	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.31	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)

Latest BHVN, FOLD, BBIO, EBS, and ARNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARNA Arena Pharmaceuticals	0.05	8.59	8.59
BBIO BridgeBio Pharma	N/A	4.57	4.54
BHVN Biohaven	N/A	2.33	2.33
EBS Emergent Biosolutions	1.20	6.32	3.51
FOLD Amicus Therapeutics	2.02	3.34	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARNA Arena Pharmaceuticals	83.77%
BBIO BridgeBio Pharma	99.85%
BHVN Biohaven	88.78%
EBS Emergent Biosolutions	78.40%
FOLD Amicus Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARNA Arena Pharmaceuticals	2.41%
BBIO BridgeBio Pharma	18.20%
BHVN Biohaven	16.00%
EBS Emergent Biosolutions	1.20%
FOLD Amicus Therapeutics	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARNA Arena Pharmaceuticals	448	61.66 million	60.17 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BHVN Biohaven	239	102.11 million	85.78 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable

BHVN, FOLD, BBIO, EBS, and ARNA Headlines

Recent News About These Companies

Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease Treatment

July 3 at 12:20 PM | tipranks.com

Amicus Therapeutics Advances Pompe Disease Research with New Observational Study

July 3 at 12:20 PM | tipranks.com

Amicus Therapeutics, Inc. (FOLD) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Amicus Therapeutics stock hits 52-week low at $5.55

June 25, 2025 | investing.com

Japan approves Amicus Therapeutics' treatment for late-onset Pompe disease

June 25, 2025 | investing.com

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

June 25, 2025 | globenewswire.com

Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment

June 24, 2025 | msn.com

Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month Low - Time to Sell?

June 23, 2025 | marketbeat.com

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

June 20, 2025 | globenewswire.com

SG Americas Securities LLC Acquires 58,496 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 20, 2025 | marketbeat.com

Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low - Time to Sell?

June 17, 2025 | marketbeat.com

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

June 16, 2025 | globenewswire.com

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts

June 14, 2025 | marketbeat.com

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

June 13, 2025 | globenewswire.com

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

June 12, 2025 | globenewswire.com

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

June 12, 2025 | seekingalpha.com

Wedge Capital Management L L P NC Decreases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

June 11, 2025 | marketbeat.com

Zacks Research Analysts Decrease Earnings Estimates for FOLD

June 6, 2025 | marketbeat.com

New Strong Sell Stocks for June 3rd

June 3, 2025 | zacks.com

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

June 3, 2025 | globenewswire.com

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

May 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, FOLD, BBIO, EBS, and ARNA Company Descriptions

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

BridgeBio Pharma NASDAQ:BBIO

$43.70 +0.88 (+2.04%)

Closing price 07/3/2025 03:50 PM Eastern

Extended Trading

$43.12 -0.59 (-1.34%)

As of 07/3/2025 04:20 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Biohaven NYSE:BHVN

$14.63 -0.13 (-0.88%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$14.66 +0.03 (+0.18%)

As of 07/3/2025 05:00 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Emergent Biosolutions NYSE:EBS

$6.99 -0.12 (-1.69%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$6.98 0.00 (-0.07%)

As of 07/3/2025 04:59 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.21 (+3.45%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$6.08 -0.08 (-1.22%)

As of 07/3/2025 04:51 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time